Objective: To apply the Michigan Neuropathy Screening Scale in social health to achieve early detection, intervention, and treatment of diabetic neuropathy in patients with type 2 diabetes mellitus. Methods: Fifty-eight patients with type 2 diabetes mellitus with weakened dorsalis pedis arteries attending the outpatient clinic of Huangtian Community Health Service Center, Bao'an District Central Hospital, Shenzhen City, China, from April to June 2023 were selected to undergo the early screening of diabetic neuropathy through MNSI, and those with abnormal results were pulled into the unified management of the micro-credit group for regular popularization of science. Before and after the management, the patients were surveyed on their understanding of diabetic neuropathy-related contents and their satisfaction with the doctors, and t-tests were performed on the two results. Results: A total of 54 valid questionnaires were obtained, of which 14 had abnormal questionnaire results, and 5 were diagnosed with diabetic neuropathy after the abnormal ones went to the hospital for electromyography. Patients' scores on the survey of understanding of diabetic neuropathy were significantly higher after management than before management (P<0.05), and their satisfaction with their doctors improved (P<0.05). The regular popularization of the WeChat group allowed patients to have a correct knowledge of diabetic neuropathy, increased attention and reduced panic, and more trust and confidence in our doctors, thus increasing the contracting rate and consultation rate of family doctors in key populations. Conclusion: MNSI is effective and convenient for early detection, intervention and treatment of diabetic neuropathy, and is worth promoting its application in social welfare.
Published in | International Journal of Diabetes and Endocrinology (Volume 8, Issue 3) |
DOI | 10.11648/j.ijde.20230803.12 |
Page(s) | 42-44 |
Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
Copyright |
Copyright © The Author(s), 2023. Published by Science Publishing Group |
Michigan Nerve Scale, Type 2 Diabetes Mellitus, Diabetic Neuropathy
[1] | Faselis C, Katsimardou A, Imprialos K, Deligkaris P, Kallistratos M, Dimitriadis K. Microvascular Complications of Type 2 Diabetes Mellitus. curr Vasc Pharmacol. 2020; 18 (2): 117-124. |
[2] | Yu Y. Gold Standard for Diagnosis of DPN. Front Endocrinol (Lausanne). 2021 Oct 26; 12: 719356. |
[3] | Zhou H, Zhang W. Gene expression profiling reveals candidate biomarkers and probable molecular mechanism in diabetic peripheral neuropathy. Diabetes Metab Syndr Obes. 2019 Jul 23; 12: 1213-1223. |
[4] | Hicks CW, Selvin E. Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes. Curr Diab Rep. 2019 Aug 27; 19 (10): 86. |
[5] | Jensen TS, Karlsson P, Gylfadottir SS, Andersen ST, Bennett DL, Tankisi H, Finnerup NB, Terkelsen AJ, Khan K, Themistocleous AC, Kristensen AG, Itani M, Sindrup SH, Andersen H, Charles M, Feldman EL, Callaghan BC. Painful and non-painful diabetic neuropathy, diagnostic challenges and implications for future management. Brain. 2021 Jul 28; 144 (6): 1632-1645. |
[6] | Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994 Nov; 17 (11): 1281-9. |
[7] | Zografou I, Iliadis F, Sambanis C, Didangelos T. Validation of Neuropad in the Assessment of Peripheral Diabetic Neuropathy in Patients with Diabetes Mellitus Versus the Michigan Neuropathy Screening Instrument, 10g Monofilament Application and Biothesiometer Measurement. curr vasc Pharmacol. 2020; 18 (5): 517-522. |
[8] | Albers JW, Pop-Busui R. Diabetic neuropathy: mechanisms, emerging treatments, and subtypes. Curr Neurol Neurosci Rep. 2014 Aug; 14 (8): 473. |
[9] | Nather A, Cao S, Chen JLW, Low AY. Prevention of diabetic foot complications. Singapore Med J. 2018 Jun; 59 (6): 291-294. |
[10] | Fernando M, Crowther R, Lazzarini P, Sangla K, Cunningham M, Buttner P, Golledge J. Biomechanical characteristics of peripheral diabetic neuropathy: a systematic review and meta-analysis of findings from the gait cycle, muscle activity and dynamic barefoot plantar pressure. Clin Biomech (Bristol, Avon). 2013 Oct; 28 (8): 831-45. |
[11] | Shi Tingzhang. A controlled study on standardized management of diabetes mellitus patients in the community by family doctor system [J]. Shanghai Medicine, 2012, 33 (20): 3. |
[12] | CHEN Hong, JING Su-Fen, PAN Hua. Evaluation of the effect of comprehensive intervention of family doctor system on glycemic control of diabetic patients in the community [J]. Shanghai Medicine, 2014, 35 (10): 3. |
[13] | Herman WH, Pop-Busui R, Braffett BH, Martin CL, Cleary PA, Albers JW, Feldman EL; DCCT/EDIC Research Group. Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in Type 1 diabetes: results from the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications. Diabet Med. 2012 Jul; 29 (7): 937-44. |
[14] | Şen HM, Şen H, Aşık M, Özkan A, Binnetoglu E, Erbağ G, Karaman HI. The importance of education in diabetic foot care of patients with diabetic neuropathy. Exp Clin Endocrinol Diabetes. 2015 Mar; 123 (3): 178-81. |
[15] | Coffey L, Mahon C, Gallagher P. Perceptions and experiences of diabetic foot ulceration and foot care in people with diabetes: a qualitative meta- synthesis. Int Wound J. 2019 Feb; 16 (1): 183-210. |
APA Style
Na Li, Xuemei Wang. (2023). Michigan Neurologic Scale in Early Screening for Diabetic Neuropathy in Patients with Type 2 Diabetes Mellitus. International Journal of Diabetes and Endocrinology, 8(3), 42-44. https://doi.org/10.11648/j.ijde.20230803.12
ACS Style
Na Li; Xuemei Wang. Michigan Neurologic Scale in Early Screening for Diabetic Neuropathy in Patients with Type 2 Diabetes Mellitus. Int. J. Diabetes Endocrinol. 2023, 8(3), 42-44. doi: 10.11648/j.ijde.20230803.12
AMA Style
Na Li, Xuemei Wang. Michigan Neurologic Scale in Early Screening for Diabetic Neuropathy in Patients with Type 2 Diabetes Mellitus. Int J Diabetes Endocrinol. 2023;8(3):42-44. doi: 10.11648/j.ijde.20230803.12
@article{10.11648/j.ijde.20230803.12, author = {Na Li and Xuemei Wang}, title = {Michigan Neurologic Scale in Early Screening for Diabetic Neuropathy in Patients with Type 2 Diabetes Mellitus}, journal = {International Journal of Diabetes and Endocrinology}, volume = {8}, number = {3}, pages = {42-44}, doi = {10.11648/j.ijde.20230803.12}, url = {https://doi.org/10.11648/j.ijde.20230803.12}, eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijde.20230803.12}, abstract = {Objective: To apply the Michigan Neuropathy Screening Scale in social health to achieve early detection, intervention, and treatment of diabetic neuropathy in patients with type 2 diabetes mellitus. Methods: Fifty-eight patients with type 2 diabetes mellitus with weakened dorsalis pedis arteries attending the outpatient clinic of Huangtian Community Health Service Center, Bao'an District Central Hospital, Shenzhen City, China, from April to June 2023 were selected to undergo the early screening of diabetic neuropathy through MNSI, and those with abnormal results were pulled into the unified management of the micro-credit group for regular popularization of science. Before and after the management, the patients were surveyed on their understanding of diabetic neuropathy-related contents and their satisfaction with the doctors, and t-tests were performed on the two results. Results: A total of 54 valid questionnaires were obtained, of which 14 had abnormal questionnaire results, and 5 were diagnosed with diabetic neuropathy after the abnormal ones went to the hospital for electromyography. Patients' scores on the survey of understanding of diabetic neuropathy were significantly higher after management than before management (PConclusion: MNSI is effective and convenient for early detection, intervention and treatment of diabetic neuropathy, and is worth promoting its application in social welfare.}, year = {2023} }
TY - JOUR T1 - Michigan Neurologic Scale in Early Screening for Diabetic Neuropathy in Patients with Type 2 Diabetes Mellitus AU - Na Li AU - Xuemei Wang Y1 - 2023/09/25 PY - 2023 N1 - https://doi.org/10.11648/j.ijde.20230803.12 DO - 10.11648/j.ijde.20230803.12 T2 - International Journal of Diabetes and Endocrinology JF - International Journal of Diabetes and Endocrinology JO - International Journal of Diabetes and Endocrinology SP - 42 EP - 44 PB - Science Publishing Group SN - 2640-1371 UR - https://doi.org/10.11648/j.ijde.20230803.12 AB - Objective: To apply the Michigan Neuropathy Screening Scale in social health to achieve early detection, intervention, and treatment of diabetic neuropathy in patients with type 2 diabetes mellitus. Methods: Fifty-eight patients with type 2 diabetes mellitus with weakened dorsalis pedis arteries attending the outpatient clinic of Huangtian Community Health Service Center, Bao'an District Central Hospital, Shenzhen City, China, from April to June 2023 were selected to undergo the early screening of diabetic neuropathy through MNSI, and those with abnormal results were pulled into the unified management of the micro-credit group for regular popularization of science. Before and after the management, the patients were surveyed on their understanding of diabetic neuropathy-related contents and their satisfaction with the doctors, and t-tests were performed on the two results. Results: A total of 54 valid questionnaires were obtained, of which 14 had abnormal questionnaire results, and 5 were diagnosed with diabetic neuropathy after the abnormal ones went to the hospital for electromyography. Patients' scores on the survey of understanding of diabetic neuropathy were significantly higher after management than before management (PConclusion: MNSI is effective and convenient for early detection, intervention and treatment of diabetic neuropathy, and is worth promoting its application in social welfare. VL - 8 IS - 3 ER -